GentiBio raises $20M seed round, licenses Treg technologies from Seattle Children’s, BRI and MIGAL

Boston-based GentiBio raised $20 million in a seed funding round and signed licensing deals with Seattle Children’s Research Institute, Benaroya Research Institute (BRI), and MIGAL to develop engineered regulatory T cells for autoimmune, alloimmune, autoinflammatory, and allergic diseases.